NCT07184619 - Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions

Treatment-resistant Schizophrenia

Interventions

DRUG

Evenamide 15 mg bid

Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment

DRUG

Placebo

Matching placebo capsules bid for a total of 12 weeks of add-on treatment

Trial Locations (5)

Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research, New York

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore

Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta

University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital, Miami

UCLA DGSOM, UCLA Health, UCLA Semel Institute, Los Angeles